Browsing Tag
SERD
3 posts
Genentech’s giredestrant shows breakthrough survival benefit in early breast cancer: What lidERA revealed
Genentech’s giredestrant delivers historic survival benefit in early-stage breast cancer. Explore how the lidERA trial may redefine endocrine therapy.
Can vepdegestrant outperform elacestrant in the race for ESR1-mutant breast cancer dominance?
Vepdegestrant shows stronger PFS benefit than elacestrant in ESR1-mutant breast cancer. Can it become the new standard? Explore data, safety, and market outlook.
PROTAC vs SERD: Is protein degradation the future of endocrine resistance treatment?
Vepdegestrant challenges oral SERDs with PROTAC innovation. Explore trial results, safety, and the future of protein degradation in breast cancer care.